Granulocyte transfusion.
OBJECTIVE
Granulocyte transfusions have been used for more than four decades. Several issues have complicated the analysis of previous studies, including the utilization of improved antimicrobials, the effects of recipient alloimmunization and variable cell dose. The use of granulocyte colony-stimulating factor for donor stimulation has revived interest in granulocyte transfusion. The aim of this review is to evaluate the most recent studies in granulocyte transfusion therapy and their clinical applicability.


RESULTS
Granulocyte colony-stimulating factor use has increased the granulocyte yield by approximately fourfold. Multiple recent studies have shown that granulocyte transfusions can be helpful in controlling severe infections progressing despite the use of appropriate antibiotics, with a response rate of 40-80% with variability in results depending on patient characteristics. This benefit is limited to a small patient population as the incidence of prolonged reversible neutropenia is relatively small. Severe side effects have been rare in those studies.


CONCLUSIONS
Granulocyte transfusions are beneficial in neutropenic patients with severe uncontrolled infection. The underlying disease process is the major determinant of outcome in these patients. Because granulocyte transfusions are not commonly used, centers are not currently able to provide transfusions in a timely fashion. Nonalloimmunized patients can receive cells from nonmatched ABO compatible donors, while alloimmunized patients should receive granulocytes from either HLA-matched donors or donors selected by leukoagglutination or lymphocytotoxicity crossmatching. Further studies are needed to clarify the optimal starting time and frequency of transfusions, and the best method for identifying donor-recipient compatibility.
Atallah
Ehab
E
Divison of Hematology/Oncology, Karmanos Cancer Institute, Detroit, Michigan 48201, USA.
Schiffer
Charles A
CA
D000017:ABO Blood-Group System; D001782:Blood Donors; D006098:Granulocytes / Q000637:transplantation*; D006648:Histocompatibility; D006650:Histocompatibility Testing; D006801:Humans; D007239:Infections / Q000209:etiology / Q000628:therapy*; D017708:Leukocyte Transfusion / Q000009:adverse effects; D009503:Neutropenia / Q000150:complications / Q000628:therapy*
D000017:ABO Blood-Group System